Effectiveness of Magnetite Nanoparticles Stabilized by 3-hydroxypyridine Derivative and Polyvinyl Pyrrolidone in Experimental Therapy of Acute Blood Loss

One of the preconditions of biomedical use of iron oxide nanoparticles including magnetite is their stabilization in liquid medium, wherein the covering substances largely determine pharmacological activity and toxicity of such nanoparticles. We obtained nanofluid that contains magnetite nanoparticles stabilized with 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) and polyvinyl pyrrolidone (PVP). Its anti-anemic properties have not been studied previously.

The aim of the investigation was to study the effect of magnetite nanoparticles stabilized with Mexidol and PVP on hematological parameters of laboratory animals in the norm and after acute blood loss.

Materials and Methods. Experiments were performed on 109 albino male rats. The liquid containing magnetite nanoparticles stabilized with Mexidol and PVP was administered to intact animals and rats after blood loss in the dose of 1.35 mg Fe/kg. Its effects were compared with the action of standard iron preparation Ferrum Lek (1.25 mg Fe/kg) as a reference drug. We determined red blood cells count, total hemoglobin, hematocrit, erythrocyte indices as well as reticulocytes content in blood 3 and 72 h after the administration of the nanofluid and the reference preparation.

Results. Nanofluid stimulates erythropoiesis in intact animals that is characterized by the increase in red blood cells count, total hemoglobin and hematocrit, which, however, are within the normal range. In anemia induced by acute blood loss, the nanofluid helps to restore these parameters and increases significantly the number of reticulocytes in blood. In both cases, the effects of the nanofluid are more pronounced than those of the reference preparation that can be due to better bioavailability of iron in the nanofluid, with Mexidol being used as one of stabilizing agents.

Conclusion. Magnetite nanoparticles stabilized with Mexidol and PVP stimulate erythropoiesis in the norm and in acute blood loss that is potentiated by the presence of succinate-containing 3-hyroxypyridine derivative as their constituent. The efficiency of magnetite nanoparticles and the possibility to use them as nanofluid offer the prospect of developing a new pharmaceutical form to correct anemic conditions based on these nanoparticles.

1. McIntyre R.A. Common nano-materials and their use in real world applications. Sci Prog 2012; 95(Pt 1): 1–22, http://dx.doi.org/10.3184/003685012x13294715456431.
2. Nikiforov V.N. Biomedical applications of magnetic nanoparticles. Nauka i tehnologii v promyishlenosti 2011; 1: 90–99.
3. Urban C., Urban A.S., Charron H., Joshi A. Externally modulated theranostic nanoparticles. Transl Cancer Res 2013; 2(4): 292–308, http://dx.doi.org/10.3978/j.issn.2218-676X.2013.08.05.
4. Zhao X., Zhao H., Chen Z., Lan M. Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent. J Nanosci Nanotechnol 2014; 14(1): 210–220, http://dx.doi.org/10.1166/jnn.2014.9192.
5. Laurent S., Saei A.A., Behzadi S., Panahifar A., Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv 2014; 11(9): 1449–1470, http://dx.doi.org/10.1517/17425247.2014.924501.
6. Wang S.Y., Liu M.C., Kang K.A. Magnetic nanoparticles and thermally responsive polymer for targeted hyperthermia and sustained anti-cancer drug delivery. Adv Exp Med Biol 2013; 765: 315–321, http://dx.doi.org/10.1007/978-1-4614-4989-8_44.
7. Rosner M.H., Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011; 4(4): 399–406, http://dx.doi.org/10.1586/ehm.11.31.
8. Yoon M., Tománek D.J. Equilibrium structure of ferrofluid aggregates. J Phys Condens Matter 2010; 22(45): 455105, http://dx.doi.org/10.1088/0953-8984/22/45/455105.
9. Liu J., Sun Z., Deng Y., Zou Y., Li C., Guo X., Xiong L., Gao Y., Li F., Zhao D. Highly water-dispersible biocompatible magnetite particles with low cytotoxicity stabilized by citrate groups. Angew Chem Int Ed Engl 2009; 48(32): 5875–5879, http://dx.doi.org/10.1002/anie.200901566.
10. Behrens S. Preparation of functional magnetic nanocomposites and hybrid materials: recent progress and future directions. Nanoscale 2011; 3: 877–892, http://dx.doi.org/10.1039/c0nr00634c.
11. Simberg D., Park J.H., Karmali P.P., Zhang W.M., Merkulov S., McCrae K., Bhatia S.N., Sailor M., Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009; 30(23–24): 3926–3933, http://dx.doi.org/10.1016/j.biomaterials.2009.03.056.
12. Vazhnichaya Ye.M., Mokliak Ye.V., Movchan B.A., Kurapov Yu.A., Zabozlaev A.A. Sposob polucheniya biologicheski aktivnoy nanozhidkosti na osnove nanochastits oksida zheleza (ІІ, ІІІ) i proizvodnogo 3-gidroksipiridina [Method of obtaining of biologically active nanofluid on the base of iron oxide (II, III) nanoparticle and 3-hydroxypyridine derivative]. Patent RU 2493857. 2012.
13. Doklinicheskie issledovaniya lekarstvennyih sredstv [Preclinical investigations of medicinal drugs]. Edited by Stefanov O.V. Kiev: Avitcena; 2001; 528 p.
14. Paton B.Ye., Movchan B.A., Kurapov Yu.A., Yakovchuk K.Yu. Sposob polucheniya nanochastits sistemy metall-kislorod s zadannym sostavom, elektronno-luchevym ispareniem i kondensatsiey v vakuume [Method of obtaining nanoparticles of metal-oxygen system with given composition by electron beam evaporation and condensation in vacuum]. Patent UA 92556. 2009.
15. Meksidol: instruktsiya, opisanie [Mexidol: instruction, description], http://health.mail.ru/drug/mexidol/.
16. Polivinilpirrolidon nizkomolekulyarnyy meditsinskiy 8000±2000 [Polyvinylpyrrolidone of low molecular weight medicinal 8000±2000]. ФСП 42-0345-4367-03: РN002600/01-2003, http://www.sintvita.ru/docs/povidone8000.pdf.
17. Ferrum Lek: instruktsiya, opisanie [Ferrum Lek: instruction, description], http://it-apharm.ru/ferrum_lek.html.
18. Antonov V.S., Bogomolova N.V., Volkov A.S. Automatization of hematological analysis. Spravochnik zaveduyushchego kliniko-diagnosticheskoy laboratoriey 2010; 1, http://www.mcfr.ru/journals/41/256/17837/.
19. Metody klinicheskikh laboratornykh issledovaniy [Methods of clinical laboratory investigations]. Edited by Kamyishnikov V.S. Moscow: MEDpress-inform; 2013; 736 p.
20. Giknis M.L.A., Clifford Ch.B. Clinical laboratory parameters for Crl:WI(Han). Charles River Laboratories 2008, http://www.criver.com/files/pdfs/rms/wistarhan/rm_rm_r_ wistar_han_clin_lab_parameters_08.aspx.
21. Moroz B.B., Deshevoi Iu.B., Sukoian G.V., Voronina T.A., Lyrshchikova A.V., Lebedev V.G. The influence of Mexidol on post-radiation recovery of hemopoietic system. Radiats Biol Radioecol 2009; 49(1): 90–96.
22. Vlasenko N.O., Vazhnicha O.M. The influence of 2-ethyl-6-methyl-3-oxypyridine succinate on regenerative reaction of erythron at an acute blood loss. Farmatsevtichniy chasopis 2013; 1(25): 181–185.
23. Pogorelov V.M., Kozinets G.I., Kovaleva L.G. Laboratorno-klinicheskaya diagnostika anemiy [Laboratory and clinical diagnosis of anemias]. Moscow: MIA; 2004; 173 p.
24. Patofiziologiya. Т. 2 [Pathophysiology. Vol. 2]. Edited by Novitskiy V.V., Goldberg E.D., Urazova O.I. Moscow: GEOTAR-Media 2009; 640 p.
25. Rumyantsev A.G., Morschakova E.F., Pavlov A.D. Eritropoetin v diagnostike, profilaktike i lechenii anemiy [Erythropoietin in the diagnosis, prevention and treatment of anemias]. Moscow; 2003; 448 p.
26. Paulson R.F., Shi L., Wu D.C. Stress erythropoiesis: new signals and new stress progenitor cells. Curr Opin Hematol 2011; 18(3): 139–145, http://dx.doi.org/10.1097/MOH.0b013e32834521c8.
27. Karpikova N.I., Peteryuhina A.A. Use of the preparation Mexidol for the treatment of patients with cerebrovascular diseases of the brain. Bulleten’ eksperimental’noj biologii i mediciny 2006; Suppl. 1: 32–33.
28. Neogemodez: instruktsiya po primeneniyu i otzyvy [Neohemodes: instruction for use and feedback], https://health.mail.ru/drug/neohemodez.
29. Lukyanova L.D., Germanova E.L., Tsybina T.A., Chernobaeva G.N. Energotropic effect of succinate-containing derivatives of 3-hydroxypyridine. Bulleten’ eksperimental’noj biologii i mediciny 2009; 147(10): 388–392.
30. Iron and heme metabolism, http://themedical­bio­chemistrypage.org/heme-porphyrin.php.

Vazhnichaya Ye.M., Mokliak Ye.V., Zabozlaev A.A. Effectiveness of Magnetite Nanoparticles Stabilized by 3-hydroxypyridine Derivative and Polyvinyl Pyrrolidone in Experimental Therapy of Acute Blood Loss. Sovremennye tehnologii v medicine 2015; 7(2): 84, https://doi.org/10.17691/stm2015.7.2.11